Bugging the Bugs: Novel Approaches in the Strategic Management of Resistant Staphylococcus aureus Infections

Author:
Open Access
Publisher website
Google Scholar
Abstract
Antibiotic resistance across multiple organisms represents an alarmingly increasing trend [1]. In 2004, nearly 2 million people in the United States were estimated to have acquired infections while hospitalized, of whom an estimated 90,000 died [2]. More than 70% of the bacteria that caused these infections were resistant to ⩾1 of the drugs commonly used for their treatment. Not surprisingly, the total cost of antimicrobial resistance to US society is significant, approaching $5 billion annually, a figure that captures the increased costs associated with treating drug-resistant nosocomial infections [3]. The Infectious Diseases Society of America cites the need for new antibiotics to combat the new resistant bacterial “superbug” infections [3]. Therefore, new antibiotics that offer better coverage, lower resistance potential, and improved adverse-effect profiles provide hope for treating resistant infections and for keeping the incidence of resistance in check.

This publication has 8 references indexed in Scilit: